Sarepta shareholders approve 2.5M share increase to 2018 equity plan

Sarepta Therapeutics, Inc.

Shareholders approved 2018 Plan Amendment, increasing authorized shares by 2.5M to 10,687,596.
All four Class I director nominees elected: Boor, Chambers, Ingram, Wigzell.
Advisory say-on-pay passed with 62,746,933 for (93.2% of votes cast).
KPMG ratified as independent auditor for 2022 with 73,729,807 for.
Equity plan vote: 62,644,364 for, 4,572,292 against, 55,530 abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.